Results 121 to 130 of about 829,432 (304)
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley +1 more source
A Qualitative Assessment of the Benefits and Costs of On-Farm Food Safety and Environmental Farm Plans in the Dairy Sector [PDF]
This series of six reports entitled: "On-Farm Food Safety and Environmental Farm Plans: Identifying and Classifying Benefits and Costs" was initiated soon after the launch of the Agricultural Policy Framework (APF) in 2002.
Gervais, Jean-Philippe +4 more
core
A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Plasma p‐Tau217 leaves 30%–50% of patients in an indeterminate “gray zone” often requiring Aβ‐PET. We developed GRAD (Gatekeeper‐Reflex for Alzheimer's Disease), a two‐stage Aβ‐positivity prediction model to improve classification while reserving Aβ‐PET for residual uncertainty.
Harthik Parankusham +7 more
wiley +1 more source
Price Stability vs. Low Inflation in Germany: An Analysis of Costs and Benefits [PDF]
We empirically investigate the costs and benefits of going from low inflation to price stability in the case of Germany. Recent empirical evidence on the sacrifice ratio suggests that the break-even point at which the permanent benefits of reducing the ...
Karl-Heinz Todter, Gerhard Ziebarth
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Blood‐based biomarkers are increasingly used to identify Alzheimer's disease (AD) pathology and may play an important role in early disease screening and participant selection for clinical trials. However, their performance across stages of cognitive impairment remains unclear. This study examined whether plasma biomarkers differ in
Maryam Abdolmaleki +7 more
wiley +1 more source
An Analysis of the Ninth Government Report on the Costs and Benefits of Federal Regulations [PDF]
This paper critically reviews the draft of the Office of Management and Budget's ninth report on the benefits and costs of federal regulation. The draft report is similar to previous reports, and does not break new ground. We offer seven recommendations,
Hahn, Robert W., Litan, Robert E.
core
Transport costs do not negate the benefits of agricultural carbon mitigation options
, 2000 It has been suggested that some agricultural carbon (C) mitigation options will yield no net C benefit under full carbon accounting (i.e. when costs are included alongside benefits). The largest likely C cost of implementing many options is the fuel cost
Smith, P., Smith, T. J. F., Smith, Pete
core +1 more source
Arthritis Care &Research, EarlyView.Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos +2 more
wiley +1 more source
Costs and Benefits of RES in Europe up to 2030. DIA-Core Policy Brief, 24 June 2014 [PDF]
, 2015 Introduction. This Policy Brief follows-up on the DIA-CORE Policy Brief on “Assessing costs and benefits of deploying renewables”, dated 26 September 2014, which highlighted the complexities in making a comprehensive and appropriate assessment of ...
Behrens, Arno +3 more
core
Animal models of osteoarthritis : the benefits and costs of reducing variability. [PDF]
Bone Joint Res, 2022 Little CB, Zaki S, Blaker CL, Clarke EC.
europepmc +1 more source